Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.91 Insider Own58.20% Shs Outstand2.94M Perf Week1.56%
Market Cap23.67M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.17M Perf Month18.70%
Income-2.82M PEG- EPS next Q- Inst Own1.12% Short Float0.27% Perf Quarter-43.44%
Sales0.43M P/S55.05 EPS this Y- Inst Trans367.94% Short Ratio0.13 Perf Half Y122.93%
Book/sh4.79 P/B0.95 EPS next Y- ROA-13.61% Short Interest0.01M Perf Year59.79%
Cash/sh0.39 P/C11.78 EPS next 5Y- ROE-13.93% 52W Range1.35 - 17.49 Perf YTD86.64%
Dividend Est.- P/FCF- EPS past 5Y34.83% ROI-10.09% 52W High-73.87% Beta1.34
Dividend TTM- Quick Ratio1.18 Sales past 5Y19.27% Gross Margin-259.62% 52W Low238.52% ATR (14)0.35
Dividend Ex-Date- Current Ratio1.18 EPS Y/Y TTM66.79% Oper. Margin-2440.69% RSI (14)45.89 Volatility3.24% 7.41%
Employees3 Debt/Eq0.14 Sales Y/Y TTM-66.71% Profit Margin-654.80% Recom1.00 Target Price80.00
Option/ShortNo / Yes LT Debt/Eq0.13 EPS Q/Q123.18% Payout- Rel Volume0.01 Prev Close4.55
Sales Surprise- EPS Surprise- Sales Q/Q-100.00% EarningsDec 22 AMC Avg Volume46.38K Price4.57
SMA20-0.61% SMA50-13.42% SMA20030.30% Trades Volume520 Change0.44%
Apr-30-24 09:15AM
Apr-12-24 06:40AM
Mar-06-24 08:00AM
Dec-22-23 04:30PM
Dec-21-23 04:30PM
11:00AM Loading…
Nov-16-23 11:00AM
Aug-10-23 02:57AM
Aug-05-23 02:53PM
Jun-22-23 08:00AM
Jun-09-23 04:30PM
May-05-23 04:31PM
May-01-23 08:00AM
Apr-28-23 09:44AM
Mar-27-23 07:00AM
08:15AM Loading…
Mar-17-23 08:15AM
Mar-03-23 07:30AM
Mar-02-23 07:30AM
Feb-10-23 04:30PM
Feb-06-23 10:08AM
Jan-23-23 06:49AM
Jan-20-23 08:00AM
Jan-04-23 09:00AM
Dec-22-22 08:00AM
Dec-16-22 08:00AM
Dec-09-22 07:00AM
Nov-25-22 08:30AM
Nov-18-22 05:30PM
06:00AM Loading…
Nov-08-22 06:00AM
Oct-07-22 03:40PM
Sep-30-22 07:42PM
Sep-23-22 08:00AM
Sep-15-22 11:58AM
Sep-02-22 06:45AM
Aug-25-22 08:31PM
Aug-19-22 08:30AM
Aug-11-22 09:45AM
May-17-22 08:13AM
May-09-22 11:41AM
May-02-22 08:00AM
Apr-29-22 04:00PM
Apr-25-22 09:30AM
Apr-22-22 08:00AM
Apr-06-22 07:00AM
Mar-22-22 05:58PM
Mar-17-22 07:00AM
Jan-25-22 10:06AM
Jan-20-22 08:47AM
Jan-18-22 08:00AM
Jan-11-22 04:56AM
Jan-10-22 08:00AM
Dec-03-21 08:00AM
Oct-19-21 08:00AM
Oct-15-21 08:00AM
Sep-15-21 09:26AM
Aug-03-21 03:01PM
Jul-15-21 02:03AM
Jul-12-21 08:59AM
Jul-09-21 08:00AM
Jun-22-21 04:00PM
Jun-21-21 08:30AM
May-26-21 08:00AM
May-24-21 12:03PM
May-13-21 07:00AM
May-06-21 07:00AM
Apr-23-21 11:35AM
Apr-22-21 09:04AM
Apr-19-21 07:00AM
Mar-31-21 07:00AM
Jan-20-21 07:32AM
Jan-16-21 01:23AM
Dec-21-20 06:00AM
Dec-10-20 08:00AM
Oct-16-20 08:00AM
Oct-02-20 04:05PM
Sep-29-20 09:00PM
Sep-08-20 03:00AM
Sep-02-20 08:00AM
Sep-01-20 02:00AM
Aug-31-20 06:05PM
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop drug molecules and certain technologies for the treatment and diagnosis of human disease conditions. The Non-Therapeutics segment encompasses diagnostics projects including a novel molecular-based rapid pathogen identification and detection diagnostics, AML Clinic, and sale of natural supplements. Its pipeline include Smart-Act, Acticule, RPIDD, Nativus, and Claves series. The company was founded by Ian Huen on September 13, 2010 and is headquartered in London, the United Kingdom.